Loading...

Menu

Καταχωρήθηκε: Δευτέρα 03 Απρ 2023

Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Tsokanas
Duration: 40 mins


The optimal selection of patients with acute myeloid leukemia (AML) for allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an area of research that continues to evolve.1 For patients with favorable-risk AML who achieve first complete remission (CR), there is a clear benefit associated with high-dose cytarabine-based consolidation chemotherapy, whereas patients with high-risk AML with adequate performance status and a suitable donor are candidates for allo-HSCT.

However, while allo-HSCT may be associated with lower rates of relapse in patients with intermediate-risk AML, there is an increased risk of transplant-related mortality. Moreover, at present, there is no agreed optimal treatment strategy for patients classified as intermediate risk; therefore, there is a need to explore the most beneficial therapy for this patient group.1

Here, we summarize the key points from the ETAL-1 trial by Bornhäuser et al.1 published in JAMA Oncology, evaluating allo-HSCT versus standard consolidation chemotherapy in patients with intermediate-risk AML.

See th full article in https://aml-hub.com/a/V6

 

 

Τηλέφωνα Επικοινωνίας:

 

Γραμματεία MMMO: 2613 603506 (ασθενείς), 2613 604062 (Γραμματεία Διευθυντή) 
Fax : 2613 604066,
email (για ιατρούς): transplant@upatras.gr,
email (για ασθενείς): mmak@upatras.gr
email (για θέματα κλινικών μελετών) : gcppatras@gmail.com
Μονάδα Μεταμόσχευσης (Νοσηλεία): 2613 603 261
Γραφείο Ιατρών: 2613 604064, 2613 604065,
Εφημερεύων Ιατρός: 2610 999111 (τηλ. κέντρο ΠΓΝΠ)

 

βρείτε μας στο χάρτη

 

Login / Sitemap

 

Copyright © 2015 - 2024 Μονάδα Μεταμόσχευσης Μυελού των Οστών Πάτρας